X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (514) 514
humans (308) 308
animals (304) 304
benzoxazoles - pharmacology (239) 239
male (227) 227
benzoxazoles - therapeutic use (203) 203
pharmacology & pharmacy (148) 148
rats (132) 132
female (124) 124
mice (121) 121
benzoxazoles - chemistry (105) 105
chemistry, medicinal (92) 92
neurosciences (92) 92
urea - analogs & derivatives (81) 81
urea - pharmacology (75) 75
analysis (72) 72
middle aged (68) 68
adult (66) 66
dose-response relationship, drug (65) 65
biochemistry & molecular biology (58) 58
article (56) 56
benzoxazoles - chemical synthesis (55) 55
rats, sprague-dawley (55) 55
structure-activity relationship (54) 54
aged (53) 53
benzoxazoles (53) 53
benzoxazole (52) 52
cell line, tumor (52) 52
benzoxazoles - administration & dosage (51) 51
time factors (50) 50
chemistry, organic (49) 49
derivatives (48) 48
benzoxazoles - adverse effects (43) 43
orexin receptors (43) 43
benzoxazoles - metabolism (41) 41
disease models, animal (41) 41
orexin (41) 41
cancer (40) 40
orexins (40) 40
receptors, neuropeptide - antagonists & inhibitors (40) 40
inhibitors (39) 39
molecular structure (39) 39
research (35) 35
amyloid neuropathies, familial - drug therapy (34) 34
apoptosis - drug effects (34) 34
neurons (34) 34
expression (33) 33
oncology (33) 33
chemistry, multidisciplinary (32) 32
psychiatry (32) 32
apoptosis (31) 31
pharmacology/toxicology (31) 31
receptors, g-protein-coupled - antagonists & inhibitors (31) 31
activation (30) 30
benzoxazoles - pharmacokinetics (30) 30
care and treatment (30) 30
double-blind method (30) 30
cell proliferation - drug effects (28) 28
disease (28) 28
pyrimidines - pharmacology (28) 28
rats, wistar (28) 28
tafamidis (28) 28
anti-inflammatory agents - therapeutic use (27) 27
biomedicine (27) 27
cells (27) 27
mutation (27) 27
prealbumin - genetics (27) 27
transthyretin (27) 27
antineoplastic agents - pharmacology (26) 26
cell biology (26) 26
hypocretin (26) 26
rodents (26) 26
tor serine-threonine kinases - antagonists & inhibitors (26) 26
amyloidosis (25) 25
drugs (25) 25
in-vitro (25) 25
treatment outcome (25) 25
triazoles - pharmacology (25) 25
ventral tegmental area (25) 25
agents (24) 24
clinical neurology (24) 24
rat (24) 24
amyloid neuropathies, familial - genetics (23) 23
brain (23) 23
clinical trials as topic (23) 23
design (23) 23
enzyme inhibitors - pharmacology (23) 23
health aspects (23) 23
mice, inbred c57bl (23) 23
biological evaluation (22) 22
chemistry (22) 22
drug design (22) 22
familial amyloid polyneuropathy (22) 22
pharmacology (22) 22
piperazines - pharmacology (22) 22
prealbumin - metabolism (22) 22
proteins (22) 22
benzothiazoles (21) 21
in-vivo (21) 21
pharmacy (21) 21
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (560) 560
German (10) 10
Italian (10) 10
French (6) 6
Japanese (6) 6
Polish (3) 3
Romanian (2) 2
Spanish (2) 2
Portuguese (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Atherosclerosis, ISSN 0021-9150, 2017, Volume 261, pp. 144 - 152
Journal Article
Neurology, ISSN 0028-3878, 08/2012, Volume 79, Issue 8, pp. 785 - 792
Journal Article
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 2007, Volume 15, Issue 17, pp. 5738 - 5751
A novel series of 1-acylthiosemicarbazides, 1,2,4-triazole-5-thiones, 1,3,4-thiadiazoles and hydrazones containing 5-methyl-2-benzoxazolinones was synthesized... 
Thiosemicarbazide | Triazol | Hydrazone | Analgesic-anti-inflammatory and antimicrobial activities | Thiadiazole | 2-Benzoxazolinone | CHEMISTRY, MEDICINAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | CHEMISTRY, ORGANIC | hydrazone | 2-benzoxazolinone | CYCLOOXYGENASE | analgesic-anti-inflammatory and antimicrobial | ACYLARYLHYDRAZONES | triazol | ACID-DERIVATIVES | IN-VITRO | thiosemicarbazide | ANTITUBERCULOSIS ACTIVITY | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | activities | thiadiazole | NITRIC-OXIDE | 2-BENZOXAZOLINONE DERIVATIVES | AGENTS | ANTIFUNGAL | Analgesics - pharmacology | Triazoles - chemistry | Crystallography, X-Ray | Structure-Activity Relationship | Analgesics - chemical synthesis | Thiadiazoles - chemistry | Thiadiazoles - therapeutic use | Anti-Bacterial Agents - chemistry | Hydrazones - therapeutic use | Semicarbazides - pharmacology | Semicarbazides - chemistry | Anti-Inflammatory Agents - therapeutic use | Triazoles - chemical synthesis | Molecular Structure | Thiadiazoles - pharmacology | Triazoles - therapeutic use | Microbial Viability - drug effects | Anti-Inflammatory Agents - pharmacology | Models, Molecular | Edema - drug therapy | Hydrazones - chemical synthesis | Semicarbazides - therapeutic use | Hydrazones - chemistry | Hydrazones - pharmacology | Anti-Bacterial Agents - chemical synthesis | Semicarbazides - chemical synthesis | Triazoles - pharmacology | Animals | Anti-Inflammatory Agents - chemistry | Benzoxazoles - chemistry | Thiadiazoles - chemical synthesis | Analgesics - chemistry | Hindlimb - drug effects | Anti-Bacterial Agents - pharmacology | Anti-Inflammatory Agents - chemical synthesis | Mice | Methylation | Edema - pathology | Index Medicus
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 02/2015, Volume 14, Issue 2, pp. 395 - 406
The mammalian target of rapamycin (mTOR) is a serine/ threonine protein kinase that exists in two complexes (mTORC1 and mTORC2) and integrates extracellular... 
MAMMALIAN TARGET | SYNOVIAL SARCOMA | MESSENGER-RNA TRANSLATION | ACTIVATION | ONCOLOGY | AKT/MAMMALIAN TARGET | EMBRYONAL RHABDOMYOSARCOMA | CELL-CYCLE | COMPLEX 2 | RAPAMYCIN PATHWAY | P70 S6 KINASE | Osteosarcoma - drug therapy | Benzoxazoles - pharmacology | TOR Serine-Threonine Kinases - metabolism | Apoptosis - drug effects | Humans | Antineoplastic Agents - therapeutic use | Mechanistic Target of Rapamycin Complex 2 | Pyrimidines - chemistry | Mechanistic Target of Rapamycin Complex 1 | Multiprotein Complexes - antagonists & inhibitors | Adenosine Triphosphate - pharmacology | TOR Serine-Threonine Kinases - antagonists & inhibitors | Multiprotein Complexes - metabolism | Protein Kinase Inhibitors - chemistry | Inhibitory Concentration 50 | Female | Antineoplastic Agents - pharmacology | Phosphorylation - drug effects | Disease Models, Animal | Benzoxazoles - therapeutic use | Pyrimidines - pharmacology | Antineoplastic Agents - chemistry | Down-Regulation - drug effects | Sarcoma - drug therapy | Sirolimus - pharmacology | Xenograft Model Antitumor Assays | Animals | Benzoxazoles - chemistry | Substrate Specificity - drug effects | Mice, Nude | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Cell Line, Tumor | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Index Medicus | mTOR | Rapamycin | MLN0128
Journal Article
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 07/2010, Volume 334, Issue 1, pp. 310 - 317
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2018, Volume 379, Issue 11, pp. 1007 - 1016
Journal Article
Journal Article
American Journal of Hematology, ISSN 0361-8609, 04/2016, Volume 91, Issue 4, pp. 400 - 405
The PI3K/AKT/mTOR signaling pathways are frequently dysregulated in multiple human cancers, including multiple myeloma (MM), non‐Hodgkin lymphoma (NHL), and... 
MAMMALIAN TARGET | RAPAMYCIN | INTERNATIONAL WORKSHOP | MTOR INHIBITION | RESPONSE CRITERIA | EVEROLIMUS | KINASE | PATIENTS PTS | HEMATOLOGY | CANCER | PI3K INHIBITOR | Benzoxazoles - pharmacology | Recurrence | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Mechanistic Target of Rapamycin Complex 2 | Mechanistic Target of Rapamycin Complex 1 | Multiprotein Complexes - antagonists & inhibitors | TOR Serine-Threonine Kinases - antagonists & inhibitors | Multiple Myeloma - drug therapy | Neoplasm Grading | Waldenstrom Macroglobulinemia - drug therapy | Aged, 80 and over | Female | Antineoplastic Agents - pharmacology | Waldenstrom Macroglobulinemia - diagnosis | Lymphoma, Non-Hodgkin - drug therapy | Multiple Myeloma - diagnosis | Administration, Oral | Benzoxazoles - therapeutic use | Treatment Outcome | Pyrimidines - pharmacology | Retreatment | Maximum Tolerated Dose | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Aged | Protein Kinase Inhibitors - pharmacology | Drug Monitoring | Neoplasm Staging | Lymphoma, Non-Hodgkin - diagnosis | Medical research | Care and treatment | Relapse | Plasma physics | Multiple myeloma | Clinical trials | Medicine, Experimental | Lymphomas | Nausea | Diseases | TOR protein | Thrombocytopenia | Creatinine | Toxicity | Urticaria | Mucosa | Fatigue | AKT protein | Patients | Lymphoma | 1-Phosphatidylinositol 3-kinase | Stomatitis | Asthenia | Vomiting | Pharmacokinetics | Drug dosages | Hodgkin's disease | Neutropenia | Macroglobulinemia | Index Medicus
Journal Article
Journal of Pharmacological Sciences, ISSN 1347-8613, 06/2016, Volume 131, Issue 2, pp. 110 - 117
Journal Article